RxDoctor Payments Data

Phillip Toth

Internal Medicine · Indianapolis, INNPI 1891098034

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (59.4%), food and beverage and education — rather than concentrated in one kind of arrangement. Novo Nordisk AS accounts for 88.2% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $592 and has fallen 89.1% since, to $65 in 2025.

$671in general payments, 2019–2025

Across 6 payments — averaging $111.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$592
  • Novo Nordisk$65
  • Echosens North America, Inc.$14
$3,218,985in research payments, 2019–2025

Across 1,275 payments — averaging $2524.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$1.5M
  • AstraZeneca$784K
  • Eli Lilly$520K
  • Pfizer$218K
  • Novartis$186K
  • Akcea Therapeutics, Inc.$27K
  • plus $16K from 4 others

What the payments were for

  • Travel & lodging$39959%
  • Food & beverage$20831%
  • Education$6510%

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$671 in reported general payments places this provider in the 70th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana →

Other internal medicine in Indianapolis

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →